Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) (STO: SOBI)
today announced that Milan Zdravkovic has been appointed Senior Vice President,
Head of Research & Development (R&D).
Milan joins Sobi from Novo Nordisk where he has had an 18 year tenure in the
Research and Development organisation responsible for therapeutic areas
including diabetes, growth hormone deficiency, obesity and immunology. Milan’s
experience spans early stage development to post-approval life-cycle management
in these areas. His most recent role was as Corporate Vice President, Obesity.
“We are delighted to welcome Milan to Sobi”, said Geoffrey McDonough, President
and CEO at Sobi. “Milan brings a creative global translational and development
profile which can build and expand upon our strong legacy of biologics
Milan will lead Sobi’s R&D efforts from post-proof of concept to late life cycle
development, focusing on advancing and expanding Sobi’s early and mid-stage
pipeline under a unified innovation strategy.
“I am looking forward to joining the team at Sobi and to advancing Sobi’s
mission to develop and deliver innovative therapies to people with rare
diseases,” said Milan.
Milan will join Sobi on 1 November 2016.
- - -
Sobi is an international specialty healthcare company dedicated to rare
diseases. Sobi’s mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a
portfolio of specialty and rare disease products across Europe, the Middle East,
North Africa and Russia for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq
Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations Investor relations
Linda Holmström, Sr Jörgen Winroth, Vice
Communications Manager President, Head of Investor
T: + 46 708 73 40 95, + 46 T: +1 347-224-0819, +1 212
8 697 31 74 -579-0506, +46 8 697 2135
The above information was released for public distribution on 26 September 2016,
at 08:00 CET.
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00 www.sobi.comGlobeNewswireglobenewswire.com
Last updated on: 26/09/2016